920525-77-5

Upstream product

• 53392-07-7 4-(4-methylphenyl)butan-1-ol 
• 1044695-80-8 4-(4-methylphenyl)butyl-tert-butyldimethylsilyl ether 
• 1044695-77-3 4-(4-bromomethylphenyl)butyl-tert-butyldimethylsilyl ether 
• 920525-76-4 methyl 2-(4-(4-(tert-butyldimethylsilanyloxy)-butyl)-phenyl)-acetate 
• 1044696-34-5 4-(4-tert-butyldimethylsilyloxybutyl)phenylacetic acid 

Downstream Products

• 1044696-38-9 4-(2-(4-(4-tert-butyldimethylsilyloxybutyl)phenyl)ethoxy)quinazoline 
• 863888-07-7 toluene-4-sulfonic acid 4-{4-[2-(quinazolin-4-yl)oxyethyl]phenyl}butyl ester 
• 920525-78-6 methanesulfonic acid 2-(4-(4-(tert-butyldimethylsilanyloxy)-butyl)-phenyl)-ethyl ester 

Relevant academic research and scientific papers

Contrast agents for applications including perfusion imaging

The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-I, and an imaging moiety, and scanning the subject using diagnostic imaging.

NOVEL CHROMEN-2-ONE BASED HYDROXAMIC ACID DERIVATIVES HAVING ANTI-INFLAMMATORY ACTIVITY, THE PREPARATION THEREOF AND A COMPOSITION CONTAINING THE SAME FOR TREATING INFLAMMATORY DISEASE

The present invention relates to novel chromen-2-one based hydroxamic acid derivatives having anti-inflammatory activity, the preparation thereof and a composition containing the same for treating inflammatory disease.

Contrast agents for myocardial perfusion imaging

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.